Halper Sadeh LLC Investigates Whether UTZ, BLFS, NRIM Are Obtaining Fair Deals for Their Shareholders

GlobeNewswire··Read original
2▲0 ▼0Impact / 5
Summary · why it matters

Halper Sadeh LLC, an investor rights law firm, is investigating whether Utz Brands, BioLife Solutions, and Northrim BanCorp are obtaining fair deals for their shareholders. The firm is examining Utz Brands' sale to Intersnack Group GmbH & Co. KG for $14.25 per share in cash, BioLife Solutions' sale to Repligen Corporation for $11.25 per share in cash and 0.1442 shares of Repligen common stock, and Northrim BanCorp's merger with PBCO Financial Corporation. Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief on behalf of shareholders. The firm notes that insiders may receive substantial financial benefits not available to ordinary shareholders and that the proposed transactions may contain terms limiting superior competing offers. Shareholders are encouraged to contact the firm at no cost to discuss their legal rights and options.

Impact on assets 4

Biotech & Genomic Medicine▲
BioLife Solutions Inc
BLFS
± MixedCapitalrelevance

BioLife Solutions is being acquired by Repligen; the law firm is investigating whether the deal is fair, which could lead to improved terms or no change.

Repligen Corporation
RGEN
± MixedCapitalrelevance

Repligen is the acquirer of BioLife Solutions; the investigation may affect the deal terms or completion, but Repligen is not the primary subject.

Financials▲
Northrim BanCorp Inc
NRIM
± MixedCapitalrelevance

Northrim BanCorp is merging with PBCO Financial; the law firm is investigating the fairness of the deal, which could affect shareholder value.

Consumer Staples▲
Utz Brands Inc
UTZ
± MixedCapitalrelevance

Utz Brands is being sold to Intersnack; the law firm is investigating whether the sale price is fair, which could lead to changes.

Off-coverage companies 1

PBCO Financial Corporationi
Private± MixedCapitalrelevance

PBCO Financial is merging with Northrim BanCorp; the investigation may affect the merger terms, but PBCO is not the primary subject.